356 Application to Market a New or Abbreviated New Drug or B

Next Page

Export Data

Import Data

Reset Form
Form Approved: OMB No. 0910-0338
Expiration Date: January 31, 2017
See PRA Statement on page 3.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

APPLICATION TO MARKET A NEW OR ABBREVIATED NEW
DRUG OR BIOLOGIC FOR HUMAN USE

1. Date of Submission (mm/dd/yyyy)

(Title 21, Code of Federal Regulations, Parts 314 & 601)
2. Name of Applicant

APPLICANT INFORMATION

3. Telephone Number (Include country code if applicable and area code) 4. Facsimile (FAX) Number (Include country
code if applicable and area code)
5. Applicant Address
Email Address

Address 1 (Street address, P.O. box, company name c/o)
Address 2 (Apartment, suite, unit, building, floor, etc.)
State/Province/Region

City

U.S. License Number if previously issued

ZIP or Postal Code

Country

6. Authorized U.S. Agent (Required for non-U.S. applicants)
Authorized U.S. Agent Name

Telephone Number (Include area code)

Address 1 (Street address, P.O. box, company name c/o)
FAX Number (Include area code)

Address 2 (Apartment, suite, unit, building, floor, etc.)
State

City

Email Address

ZIP Code

7. NDA, ANDA, or BLA Application Number

PRODUCT DESCRIPTION

8. Supplement Number (If applicable)

9. Established Name (e.g., proper name, USP/USAN name)
10. Proprietary Name (Trade Name) (If any)
11. Chemical/Biochemical/Blood Product Name (If any)
12. Dosage Form

13. Strengths

15. Proposed Indication for Use

14. Route of Administration

Is this indication for a rare disease (prevalence <200,000 in U.S.)?
Does this product have an FDA
Orphan Designation for this
indication?
Yes
No

16. Application Type
(Select one)

APPLICATION INFORMATION
17. If an NDA, identify the type

New Drug Application (NDA)

No

Contin.
Page for
#15

Biologics License Application (BLA)

Abbreviated New Drug Application (ANDA)

18. If a BLA, identify the type

505 (b)(2)

505 (b)(1)

If yes, provide the Orphan
Designation number for this
indication:

Yes

351 (a)

351 (k)

19. If a 351(k), identify the biological reference product that is the basis for the submission.
Name of Biologic:

Holder of Licensed Application:

20. If an ANDA, or 505(b)(2), identify the listed drug product that is the basis for the submission.
Name of Drug:

Application Number of Relied Upon Product:

Indicate Patent Certification(s):

P1

21. Submission (Select one)

Original

Product Correspondence

P2

P3

P4

Labeling Supplement

REMS Supplement

Section viii - MOU
CMC Supplement

Statement of no relevant patents
Efficacy Supplement

Postmarketing Requirements or Commitments

Annual Report

Periodic Safety Report

Other (Specify):

FORM FDA 356h (6/14)

Page 1 of 3

PSC Publishing Services (301) 443-6740

EF

Previous Page
22. Submission
Sub-Type

Next Page

Presubmission

Amendment

Initial Submission

Resubmission

24. Does this submission contain only pediatric data?

23. If a supplement, identify
the appropriate category.

Yes

CBE

Prior Approval (PA)

CBE-30

No

25. Reasons for Submission

26. Proposed Marketing Status (Select one)
27. This application is (Select one)

Prescription Product (Rx)

Paper

Paper and Electronic

Over-The-Counter Product (OTC)
Electronic

28. Number of Volumes Submitted

29. Establishment Information (Full establishment information should be provided in the body of the application.)
Refer to the instruction sheet (Form FDA 356h Supplement) for more information.
Establishment Name
Address 1 (Street address, P.O. box, company name c/o)

Registration (FEI) Number

Address 2 (Apartment, suite, unit, building, floor, etc.)
City

MF Number

State/Province/Region

Country

ZIP or Postal Code

Is the establishment new to the application?
Yes

Establishment DUNS Number

What is the status of the establishment?
Pending
Active

No

Inactive

Withdrawn

Establishment Contact Information
Name of Contact for the Establishment

Telephone Number (Include area code)

Address 1 (Street address, P.O. box, company name c/o)
FAX Number (Include area code)

Address 2 (Apartment, suite, unit, building, floor, etc.)
City

State/Province/Region

Country

Email Address

ZIP or Postal Code

Manufacturing Steps and/or Type of Testing

Is the site ready
Yes
for inspection?
If No, when will site be
ready? (mm/dd/yyyy)

No

N/A

Continuation Page for #29

30. Cross References (List related BLAs, INDs, NDAs, PMAs, 510(k)s, IDEs, BMFs, MAFs, and DMFs referenced in the current application.)

Contin.
Page for
#30

31. This application contains the following items (Select all that apply)
1. Index

2. Labeling (Select one):

4. Chemistry Section

Draft Labeling

Final Printed Labeling

3. Summary (21 CFR 314.50 (c))

A. Chemistry, manufacturing, and controls information (e.g., 21 CFR 314.50(d)(1); 21 CFR 601.2)
B. Samples (21 CFR 314.50 (e)(1); 21 CFR 601.2 (a)) (Submit only upon FDA’s request)
C. Methods validation package (e.g., 21 CFR 314.50(e)(2)(i); 21 CFR 601.2)

5. Nonclinical pharmacology and toxicology section
(e.g., 21 CFR 314.50(d)(2); 21 CFR 601.2)

6. Human pharmacokinetics and bioavailability section
(e.g., 21 CFR 314.50(d)(3); 21 CFR 601.2)

7. Clinical microbiology section (e.g., 21 CFR 314.50(d)(4))

8. Clinical data section (e.g., 21 CFR 314.50(d)(5); 21 CFR 601.2)
Item 31 continued on page 3

FORM FDA 356h (6/14)

Page 2 of 3

Previous Page

Next Page

31. This application contains the following items (Continued; select all that apply)
9. Safety update report (e.g., 21 CFR 314.50(d)(5)(vi)(b);
21 CFR 601.2)

10. Statistical section (e.g., 21 CFR 314.50(d)(6); 21 CFR 601.2)

11. Case report tabulations (e.g., 21 CFR 314.50(f)(1);
21 CFR 601.2)

12. Case report forms (e.g., 21 CFR 314.50 (f)(2); 21 CFR 601.2)

13. Patent information on any patent that claims the drug/
biologic (21 U.S.C. 355(b) or (c))

14. A patent certification with respect to any patent that claims the
drug/biologic (21 U.S.C. 355 (b)(2) or (j)(2)(A))

15. Establishment description (21 CFR Part 600, if applicable)

16. Debarment certification (FD&C Act 306 (k)(1))

17. Field copy certification (21 CFR 314.50 (l)(3))

18. User Fee Cover Sheet (PDUFA Form FDA 3397, GDUFA Form
FDA 3794, BsUFA Form FDA 3792, or MDUFMA Form FDA 3601)

19. Financial Disclosure Information (21 CFR Part 54)
20. Other (Specify):

CERTIFICATION
I agree to update this application with new safety information about the product that may reasonably affect the statement of contraindications,
warnings, precautions, or adverse reactions in the draft labeling. I agree to submit safety update reports as provided for by regulation or as
requested by FDA. If this application is approved, I agree to comply with all applicable laws and regulations that apply to approved applications,
including, but not limited to, the following:
1. Good manufacturing practice regulations in 21 CFR Parts 210, 211 or applicable regulations, Parts 606, and/or 820.
2. Biological establishment standards in 21 CFR Part 600.
3. Labeling regulations in 21 CFR Parts 201, 606, 610, 660, and/or 809.
4. In the case of a prescription drug or biological product, prescription drug advertising regulations in 21 CFR Part 202.
5. Regulations on making changes in application in FD&C Act section 506A, 21 CFR 314.71, 314.72, 314.97, 314.99, and 601.12.
6. Regulations on Reports in 21 CFR 314.80, 314.81, 600.80, and 600.81.
7. Local, state, and Federal environmental impact laws.
If this application applies to a drug product that FDA has proposed for scheduling under the Controlled Substances Act, I agree not to market
the product until the Drug Enforcement Administration makes a final scheduling decision.
The data and information in this submission have been reviewed and, to the best of my knowledge, are certified to be true and accurate.
Warning: A willfully false statement is a criminal offense, U.S. Code, title 18, section 1001.
32. Typed Name and Title of Applicant’s Responsible Official
34. Telephone Number (Include country
code if applicable and area code)

33. Date (mm/dd/yyyy)

35. FAX Number (Include country code if
applicable and area code)

36. Email Address

37. Address of Applicant’s Responsible Official
Address 1 (Street address, P.O. box, company name c/o)
Address 2 (Apartment, suite, unit, building, floor, etc.)
City

State/Province/Region

Country

ZIP or Postal Code

38. Signature of Applicant’s Responsible Official or
Other Authorized Official

Sign

39. Countersignature of Authorized U.S. Agent

Sign

The information below applies only to requirements of the Paperwork Reduction Act of 1995.
The burden time for this collection of information is estimated to average 24 hours per response,
including the time to review instructions, search existing data sources, gather and maintain the
data needed and complete and review the collection of information. Send comments regarding
this burden estimate or any other aspect of this information collection, including suggestions
for reducing this burden to the address to the right:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a
collection of information unless it displays a currently valid OMB number.”

DO NOT SEND YOUR COMPLETED FORM
TO THIS PRA STAFF EMAIL ADDRESS.

FORM FDA 356h (6/14)

Page 3 of 3